(110 days)
The OMNIVision™ system is intended to be used as an intra-operative system to assist in the alignment of prosthetic components during Total Hip Arthroplasty, where a reference to a rigid anatomical structure can be identified. The system achieves this by displaying intra-operative measurements of the acetabular component to the user calculated from visual information from a camera detecting fiducial markers.
The OMNIVision™ system is compatible for use with the legally marketed products
- · OPSInsight™ and
- · the Corin TrinityTM Acetabular System,
- · Trinity-iTM Acetabular shells and
- · TrinityTM non-occluded titanium plasma sprayed (TPS) acetabular shells.
The OMNI Vision™ system is indicated for use with the posterior, anterior surgical approaches for primary Total Hip Arthroplasty.
The OMNIVision™ system is an image-based navigation system intended to assist the surgeon in delivering a target acetabular cup placement during Total Hip Arthroplasty (THA). The system consists of a Camera Assembly, OMNIVision™ software application installed onto the laptop, fiducial markers used to track the position of the surgical instruments, and a single use sterile drape. The fiducial markers and camera drape are supplied in packaged and EtO sterilized condition.
The OMNIVision™ system displays real-time intraoperative information, cup alignment and cup depth, with augmented and virtual reality views using a fixed reference attached to the patient's pelvis. The workflow of the OMNIVision™ system involves instrument calibration, registration of patient anatomy, and determination of cup alignment. The system uses image-based registration of the patient's anatomy and matches it to the pre-operative CT images of the patient's anatomy, the OMNIVision System to intra operatively calculate and display the information relative to the patient's anatomy, and independent of the patient's intra-operative pelvic position.
The OMNIVision™ System is designed for use with the Corin Trinity Acetabular System components and compatible with the Corin OPSInsight™ system for pre-operative planning.
The OMNIVision system is an image-based navigation system intended to assist the surgeon in delivering a target acetabular cup placement during Total Hip Arthroplasty (THA). The acceptance criteria for the OMNIVision system were evaluated through various studies, including cadaver surgeries and software bench testing.
Here's a breakdown of the acceptance criteria and study information:
1. Table of Acceptance Criteria and Reported Device Performance
| Parameter | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| For Cadaver Studies | ||
| Angular position | ±3° (Max. error) | ±3° |
| Linear position | ±3mm (Max. error) | ±3mm |
| For Software Bench Testing | ||
| Angular position | Not explicitly stated (bench testing implies higher precision than clinical use) | Mean ±1° |
| Linear position | Not explicitly stated (bench testing implies higher precision than clinical use) | Mean ±1mm |
| User Requirements | Established criteria for user requirements | Met established criteria |
2. Sample Size Used for the Test Set and Data Provenance
- Cadaver Studies: The document states "Surgeon-user verification studies of performance measures and accuracy performed by cadaver surgeries." The sample size for cadavers is not specified.
- Data Provenance: The cadaver studies are likely prospective, as they involve newly performed surgeries under controlled conditions to test the device. The country of origin of this data is not specified.
- Software Bench Testing: A "phantom device developed with guidance from ASTM-F2554" was used. The sample size for this testing is not specified (e.g., number of test runs or simulations).
- Data Provenance: This is a controlled laboratory environment testing, hence prospective. The country of origin is not specified, though the manufacturer is based in Australia.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
- Cadaver Studies: "Surgeon-user verification studies" implies surgeons were involved in the testing and evaluation. However, the number of experts and their specific qualifications (e.g., years of experience, specialization) used to establish ground truth or assess performance in the cadaver studies are not specified.
- Software Bench Testing: Ground truth for software bench testing would likely be based on predefined precise phantom measurements. No human experts are explicitly mentioned for establishing ground truth in this context, only in performing the tests.
4. Adjudication Method for the Test Set
The document does not specify any formal adjudication method (e.g., 2+1, 3+1, none) for either the cadaver studies or the software bench testing. The "surgeon-user verification" suggests a direct assessment by the operating surgeons for the cadaver studies.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
There is no indication that a multi-reader multi-case (MRMC) comparative effectiveness study was done. The studies described focus on the standalone performance of the device without explicit comparison to human readers with and without AI assistance for effect size quantification.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
- Yes, a standalone performance study was done through software bench testing. This testing "demonstrated mean positional accuracy of ±1° for angular position and ±1mm for linear position" using a phantom device. This represents the algorithm's performance in a controlled, non-human-interaction scenario.
- The cadaver studies represent a human-in-the-loop scenario, where surgeons used the device to achieve the reported accuracy.
7. Type of Ground Truth Used
- Cadaver Studies: The ground truth for the cadaver studies is implied to be actual measurements taken post-implantation, based on the stated "accuracy of the OMNIVision™ System in implanting an acetabular cup." This would be a direct measurement of the implanted component's position relative to known anatomical landmarks.
- Software Bench Testing: The ground truth for software bench testing was based on a "phantom device developed with guidance from ASTM-F2554." This is a precisely engineered physical model with known, accurate measurements.
8. Sample Size for the Training Set
The document does not provide information regarding the sample size for any training set for the OMNIVision system's software. The system uses "image-based registration of the patient's anatomy and matches it to the pre-operative CT images of the patient's anatomy," implying some form of image processing or machine learning, but no details on training are given.
9. How the Ground Truth for the Training Set Was Established
As no information is provided about a training set or its sample size, there is no information on how the ground truth for any potential training set was established.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo for the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. Food & Drug Administration".
April 12, 2021
Corin USA % Robert Poggie President BioVera, Inc. 65 Promenade Saint Louis Notre Dame de Llle Perrot, Quebec J7V 7P2 Canada
Re: K203751
Trade/Device Name: OMNIVision system Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic Instrument Regulatory Class: Class II Product Code: OLO Dated: January 13, 2021 Received: January 19, 2021
Dear Robert Poggie:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Shumaya Ali -S
Shumaya Ali, M.P.H. Assistant Director DHT6C: Division of Restorative. Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
510(k) Number (if known)
Device Name
OMNIVision™ system
Indications for Use (Describe)
The OMNIVision™ system is intended to be used as an intra-operative system to assist in the alignment of prosthetic components during Total Hip Arthroplasty, where a reference to a rigid anatomical structure can be identified. The system achieves this by displaying intra-operative measurements of the acetabular component to the user calculated from visual information from a camera detecting fiducial markers.
The OMNIVision™ system is compatible for use with the legally marketed products
- · OPSInsight™ and
- · the Corin TrinityTM Acetabular System,
- · Trinity-iTM Acetabular shells and
· TrinityTM non-occluded titanium plasma sprayed (TPS) acetabular shells.
The OMNI Vision™ system is indicated for use with the posterior, anterior surgical approaches for primary Total Hip Arthroplasty.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) SUMMARY
The OMNIVision™ System
In accordance with 21 CFR 807.92 of the Federal Code of Regulations, the following information is a summary of safety and effectiveness of the OMNIVision™ System.
A. SUBMITTERS INFORMATION
| Submitter Name: | BioVera, Inc. |
|---|---|
| Submitter Address: | 65 Promenade Saint-Louis, Notre-Dame-De-L'Ile-Perrot,Quebec, J7V 7P2, CANADA |
| Contact Person: | Robert A Poggie, PhD |
| Phone and Fax Numbers: | (514) 901-0796 |
| Date of Submission: | December 22, 2020 |
B. DEVICE IDENTIFICATION & MANUFACTURER
| Manufacturer Name: | Optimized Ortho Pty Ltd |
|---|---|
| Manufacturer Address: | 17 Bridge Street, Pymble, NSW, 2073, AUSTRALIA |
| Registration Number: | 3012916784 |
| Contact Name: | Crissy Tomarelli |
| Title: | Regulatory and Quality Director |
| Device Trade Name: | OMNIVision™ System |
| Device Common Name: | Stereotaxic instrument |
| Classification Name: | Stereotaxic instrument |
| Classification Code: | OLO - Class II |
| Classification Panel: | Orthopedic |
| Regulation Number: | 21 CFR 882.4560 |
C1. PRIMARY PREDICATE DEVICE K172849
Intellijoint Surgical Inc., Intellijoint HIP® Generation 2C System
C1. PREDICATE DEVICE K050615
Stryker Navigation System - CT Based Hip Module
{4}------------------------------------------------
D. DEVICE DESCRIPTION
The OMNIV/ision™ system is an image-based navigation system intended to assist the surgeon in delivering a target acetabular cup placement during Total Hip Arthroplasty (THA). The system consists of a Camera Assembly, OMNIVision™ software application installed onto the laptop, fiducial markers used to track the position of the surgical instruments, and a single use sterile drape. The fiducial markers and camera drape are supplied in packaged and EtO sterilized condition.
The OMNIVision™ system displays real-time intraoperative information, cup alignment and cup depth, with augmented and virtual reality views using a fixed reference attached to the patient's pelvis. The workflow of the OMNIVision™ system involves instrument calibration, registration of patient anatomy, and determination of cup alignment. The system uses image-based registration of the patient's anatomy and matches it to the pre-operative CT images of the patient's anatomy, the OMNIVision System to intra operatively calculate and display the information relative to the patient's anatomy, and independent of the patient's intra-operative pelvic position.
The OMNIVision™ System is designed for use with the Corin Trinity Acetabular System components and compatible with the Corin OPSInsight™ system for pre-operative planning.
E. INDICATIONS FOR USE
The OMNIV/ision™ system is intended to be used as an intra-operative system to assist in the alignment of prosthetic components during Total Hip Arthroplasty, where a rigid anatomical structure can be identified.
The system achieves this by displaying intra-operative measurements of the acetabular component to the user calculated from visual information from a camera detecting fiducial markers.
The OMNIVision™ system is compatible for use with the legally marketed products
- · OPSInsight™ and
- · the Corin Trinity™ Acetabular System,
- · Trinity-i™ Acetabular shells and
- · Trinity™ non-occluded titanium plasma sprayed (TPS) acetabular shells.
The OMNIV/ision™ system is indicated for use with the posterior, anterolateral and direct anterior surgical approaches for primary Total Hip Arthroplasty.
F. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS
The subject OMNIVision system uses both intra operative registration and pre-operative CT images of the patient's pelvic anatomy for the frames of reference for the purpose of guiding acetabular cup placement in THA surgery, and matches the pre-op and intra-op positions intra-operatively. The OMNIVision system determines position of the acetabular cup that is independent's intra-operative pelvic position. The predicate Stryker Navigation System CT Based Hip Module utilizes CT scans obtained preoperatively as a frame of reference for positioning an acetabular component. The primary predicate Intellijoint system uses intra-operative registration for the frame of reference of the pelvis, but does not utilize preoperative patient images. The table below compares technical characteristics of the subject device OMNIVision™ System and the primary predicate device, the Intellijoint HIP Generation 2C System.
{5}------------------------------------------------
| Characteristic | Subject Device, OMNIVision System | Intellijoint HIP Gen 2C System, K172849 |
|---|---|---|
| Anatomical use? | Hip | Hip |
| Function / Use | The system uses registration and ensuresmatching with pre-op patient information (CT)intra-operatively, allowing the system to calculateand display information relative to the rigid bodyreference (Pelvic Pin and Fiducial Marker), makingit independent of the patient's intra-operativepelvic position (relative to the surgical table). Thesystem is used as an adjunct to aid the surgeon inpositioning the acetabular component in THA. | The system uses registration and aids thesurgeon in performing intra-operativemeasurements including measurements of limbposition, joint center-of-rotation, and implantcomponent positioning. The system is used asan adjunct to aid the surgeon in positioning theacetabular component in THA. |
| Proprietary software? | Yes | Yes |
| Portable System? | Yes | Yes |
| Hardware | The system includes a Camera assembly, singleuse sterile drape for camera, fiducial markers ('ortrackers') and reusable tools for tracking, laptopcomputer workstation, software, and bone fixationinstruments/hardware. | The system includes an infrared camera,trackers for registration intra op, computerworkstation, software, and bone fixationinstruments / hardware. |
| Use of pre-op info? | Yes, CT scans of patient's pelvis | No |
| Intra-op registration? | Yes | Yes |
| Trackers sterile? | Yes | Yes |
G. PERFORMANCE DATA
The following tests and studies were performed to validate and verify the subject OMNIVision™ System:
- Surgeon-user verification studies of performance measures and accuracy performed by cadaver . surgeries. The results of the cadaver evaluation demonstrated that the subject device met the established criteria for user requirements. The accuracy of the OMNIVision™ System in implanting an acetabular cup was ±3° for anqular position and ±3mm for linear position.
- Software bench testing with a phantom device developed with guidance from ASTM-F2554 . demonstrated mean positional accuracy of ±1° for angular position and ±1mm for linear position.
- Validation testing of precision, accuracy, and usability of the fiducial markers after cleaning, packing, . and sterilization and in simulated use surgeries.
- . Documentation and validation of OMNIVision software were performed per the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.
- Electrical and emissions safety testing demonstrated compliance to EN 60601-1-2:2015, IEC 60601-. 1:2005 (3rd Ed.), IEC 60601-1-6:2010, EN60601-1:2006/A1:2013, ANSI/AAMI ES60601-1:2005.
- Sterility of the fiducial markers was validated per ISO 11135:2014. .
- The reusable instrument kit was validated for manual and automated cleaning methods and sterilization . by vacuum steam autoclave.
H. CONCLUSION
The OMNIVision™ System used with Corin Trinity acetabular cups was determined to be substantially equivalent to the Intellijoint and Stryker predicate devices.
§ 882.4560 Stereotaxic instrument.
(a)
Identification. A stereotaxic instrument is a device consisting of a rigid frame with a calibrated guide mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part of the nervous system.(b)
Classification. Class II (performance standards).